Small Cap Feast
Small Cap Feast – 22 June 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
What’s cooking in the IPO kitchen?
Physiomics* 6.6p £6.3m (PYC.L)
The provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is participating in the American Academy of Cancer Research (AACR) Annual Meeting 2020, being held as a virtual event.
The Company will be presenting on a new version of its Virtual Tumour™ model, which is able to simulate the efficacy of dual immuno-therapy regimens. The model was originally developed as part of a client project.
The Company will be presenting an original poster in the session “LBPO.IM02 – Late-Breaking Research: Immunology 2”, scheduled for 22 June 2020 at 9.00 a.m. – 6.00 p.m. EDT (Eastern Daylight Time). The poster is titled “Optimising dual immuno-oncology combinations with Virtual Tumour” (Abstract # LB-392). The session will include live interactions and the poster will remain available for viewing by registered attendees for at least three months after the virtual meeting.
Vast Resources 0.1975p £22.3m (VAST.L)
Vast has raised £1.5m at 0.18m. The cash raised from the Placing together with further subscription proceeds as referred to above will provide funds to cash settle the liability to Atlas Capital Markets at the end of July or during August 2020, should Atlas decide to exercise its conversion rights prior to the Company finalising the refinancing announced on 15 May 2020. At current share prices, the necessary sum to achieve this is estimated by the Directors to be of the order of US$780,000 As announced on 24 October 2019 under the Atlas Bond Issue Deed there is a six months non-conversion period from the drawdown date (30 January 2020) after which Atlas may convert up to 10% of the par value of the Bond each month.
In addition, the funds being raised will provide the Company with funding for the first month’s production at the Baita Plai Polymetallic Mine until the first sale of concentrate expected in late August, together with some further general working capital.
FastForward Innovations 6.25p £10.1m (FFWD.L)
The company focusing on making investments in fast growing and industry leading businesses, is pleased to note the update from 888Sport relating to its partnership with Leap Gaming, in which FastForward has a 43.4% interest in through its investee company, Fralis LLC. Leap Gaming’s partnership with 888 will see a variety of Leap Gaming titles become available through 888casino . The partnership will see 888sport host a selection of popular, ultra-realistic 3D virtual sports games from Leap Gaming.
SolGold 21.125p £438m (SOLG.L)
Update on the Company’s regional exploration programme throughout Ecuador. Following the hiatus of all activities due to the COVID-19 pandemic and government restrictions, SolGold has resumed exploration activities on a number of concessions with strict COVID-19 protocols in place.
Ø All regulatory approvals received for scout drilling at Porvenir, La Hueca and Blanca projects Ø Drilling equipment mobilised to Porvenir, with logistics and camp construction nearing completion Ø A drill rig is preparing to move to the La Hueca Project Ø Regional exploration programme fully funded alongside the Company’s pre-feasibility study at Alpala, following recent successful capital raising
Ø Ecuadorean government publicly recognised the critical role mineral mining and exploration industry will play in rebuilding national and local economies post COVID-19 Ø National authorities encouraging return to productive activities Ø Field activities resumed at other priority regional projects including Rio Amarillo, Chical, Cisne-Loja, Sharug and Timbara Ø SolGold working closely with all levels of government, particularly local COVID-19 Emergency Committees to ensure certain protocols are met to safely restart activities
Directa Plus 75p £45.75m (DCTA.L)
The producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that the Company has been granted its sixth Chinese patent. The grant by the Chinese Patent Office covers the use of the Company’s G+® graphene technology for bicycle, motorcycle and passenger car tyres as well as truck and bus radial tyres.
Specifically, the patent covers the formula which unlocks the potential of G+® technology for the tread component and enables manufacturers to balance the conflicting properties of rolling resistance and grip while enhancing both.
China is one of the main manufacturers of elastomeric compounds for the global tyre industry. The country’s own tyre market was estimated to be worth some US$28 billion in 2018 by TechSci Research which forecast the market to grow at a compound annual rate of over ten per cent to reach US$52 billion by 2023.
Blackbird 15.75p £52.9m (BIRD.L)
The developer and seller of the market-leading Blackbird cloud video editing platform, announced today that esports trailblazers, VENN, have selected Blackbird for ultra-fast and efficient remote video production. The deal is for 3 years and was brokered by Blackbird’s new US systems integrator partner, ASG.
VENN is a new kind of TV network for the streaming generation, aimed at gaming, pop culture and esports audiences. Founded by gaming visionaries Ariel Horn and Ben Kusin, VENN broadcasts live from studios in New York and Los Angeles with content distributed across a broad range of media platforms.
Brave Bison 1.375p £8.4m (BBSN.L)
Social video company Brave Bison recently teamed up with the Internet Watch Foundation (IWF) and the Marie Collins Foundation (MCF) to raise awareness of their child sexual abuse education campaign, “Something’s Not Right”. Comedian Arron Crascall and football YouTuber EmanSV2 were enlisted to participate in the campaign, which focused on encouraging and empowering young men to report sexual images of children online. Manning Gottlieb OMD brokered the appointment and Brave Bison was selected based on the team’s expertise and proven success in influencer marketing.
The talent-led campaign was hugely successful with Arron Crascall and EmanSV2 driving over 8.5 million user impressions and more than 5.4 million views on Instagram, meaning that Brave Bison delivered 23x higher engagement, 15x more impressions and 37x more views than expected. Further, compared to the average non-profit industry Instagram engagement rate of 1.75% and the average influencer industry Instagram engagement rate of 1.67%, the campaign’s average engagement rate was 6.9% – nearly 4x higher than the industry average.
Active Energy 0.9p £11.5m (AEG.L)
The international biomass based renewable energy business, is pleased to announce that it has completed a fundraise of £800,000 (before expenses) through the subscription of convertible loan notes by new US and existing European investors. The CLNs are being issued as part of the Company’s existing Series B CLN Instrument.
- £800,000 raised through the issuance of CLNs with the proceeds immediately deployed to accelerate the development of and increase production volumes at AEG’s Lumberton facility (“Lumberton”)
- Existing sawmill’s 2nd production shift to start mid-July
- Additional saw-log export contract signed with a new South East Asian customer
- New sales & commercial opportunities being presented to the Company at Lumberton
MYCELX 46.5p £9m (MYX.L)
The clean water technology company providing patented solutions for the Oil and Gas market and commercial industrial markets worldwide, announced the extension of a purchase order from SABIC (Saudi Basic Industries Corporation).
The contract extension with SABIC is for a leased water treatment system in the Middle East. The value of the contract extension is $1.8m. The Company continues to pursue advanced opportunities in the Middle East and to that end has agreed to run a trial at another SABIC affiliate which, if successful, has the potential to generate further incremental revenues for the Company this year.
Angle 62.5p £108m (AGL.L)
The liquid biopsy company, is announced that blood donations have recommenced in support of ANGLE’s FDA analytical studies and for patient enrolment in its pivotal ovarian cancer study.
As announced on 31 March 2020, completion of ANGLE’s remaining analytical studies in support of its US Food and Drug Administration (FDA) submission for Parsortix® had to be ceased as a result of UK Government COVID-19 lock down measures preventing blood donations from healthy volunteers. Similar restrictions in the United States impacted patient enrolment at University of Rochester Medical Centre, New York for the ovarian cancer study there.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.